• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.

作者信息

Al-Samkari Hanny, Kuter David J

机构信息

Center for Hematology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

出版信息

Br J Haematol. 2018 Oct;183(2):168. doi: 10.1111/bjh.15432. Epub 2018 Jul 5.

DOI:10.1111/bjh.15432
PMID:29978577
Abstract
摘要

相似文献

1
Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.血小板生成素受体激动剂艾曲泊帕、阿伐曲泊帕和罗米司亭在一名慢性免疫性血小板减少症患者中的相对效价。
Br J Haematol. 2018 Oct;183(2):168. doi: 10.1111/bjh.15432. Epub 2018 Jul 5.
2
Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.难治性免疫性血小板减少症中的血小板生成素受体激动剂：艾曲泊帕和罗米司亭的反应差异：一例病例报告及可能的解释。
J Clin Pharm Ther. 2012 Dec;37(6):729-32. doi: 10.1111/j.1365-2710.2012.01353.x. Epub 2012 May 14.
3
Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.成人原发免疫性血小板减少症患者血小板生成素受体激动剂转换：一项涉及 4 家西班牙中心的回顾性协作调查。
Eur J Haematol. 2017 Oct;99(4):372-377. doi: 10.1111/ejh.12932.
4
Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.罗米司亭在艾曲泊帕耐药或不耐受的免疫性血小板减少症患者中的安全性和有效性。
Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17.
5
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.转换为艾曲泊帕或罗米司亭治疗的慢性免疫性血小板减少症（ITP）患者的治疗模式和临床结局
Int J Hematol. 2015 Mar;101(3):255-63. doi: 10.1007/s12185-014-1731-7. Epub 2015 Jan 14.
6
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.在慢性免疫性血小板减少性紫癜中序贯使用罗米司亭和艾曲泊帕后无交叉耐药性。
Blood. 2013 Feb 14;121(7):1240-2. doi: 10.1182/blood-2012-11-465575.
7
A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia.免疫性血小板减少症中切换血小板生成素受体激动剂的回顾性前瞻性评估。
Haematologica. 2013 Jun;98(6):881-7. doi: 10.3324/haematol.2012.074633. Epub 2013 Feb 26.
8
Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.促血小板生成素受体激动剂用于准备接受脾切除术的成人免疫性血小板减少症患者：一项回顾性观察性 GIMEMA 研究的结果。
Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4.
9
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.血小板生成素受体激动剂：艾曲泊帕和罗米司亭用于治疗慢性免疫性血小板减少性紫癜
Clin J Oncol Nurs. 2019 Apr 1;23(2):212-216. doi: 10.1188/19.CJON.212-216.
10
Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.血小板生成素受体激动剂治疗慢性难治性原发性免疫性血小板减少症：真实临床实践中的疗效和安全性数据
Ter Arkh. 2018 Aug 17;90(7):70-76. doi: 10.26442/terarkh201890770-76.

引用本文的文献

1
Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.当前对免疫性血小板减少症的认识：发病机制和治疗选择的综述。
Int J Mol Sci. 2024 Feb 10;25(4):2163. doi: 10.3390/ijms25042163.
2
Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.促血小板生成素受体激动剂治疗化疗相关性血小板减少症的最佳管理。
Blood Rev. 2024 Jan;63:101139. doi: 10.1016/j.blre.2023.101139. Epub 2023 Oct 18.
3
Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.
新兴的促血小板生成素受体激动剂在化疗引起的血小板减少症管理中的应用数据。
Expert Rev Hematol. 2023 May;16(5):365-375. doi: 10.1080/17474086.2023.2201428. Epub 2023 Apr 14.
4
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.曾接受艾曲泊帕或罗米司亭治疗的成人免疫性血小板减少症患者换用阿伐曲泊帕治疗：一项多中心美国研究。
Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18.
5
Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia.病例报告：阿伐曲泊帕成功治疗两例抗程序性死亡受体1（PD-1）抗体诱导的获得性无巨核细胞性血小板减少症
Front Pharmacol. 2022 Jan 27;12:795884. doi: 10.3389/fphar.2021.795884. eCollection 2021.
6
Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice.成人免疫性血小板减少症（ITP）患者的管理：当前指南及临床实践经验综述
J Blood Med. 2021 Jul 26;12:653-664. doi: 10.2147/JBM.S259101. eCollection 2021.
7
The role of romiplostim for pediatric patients with immune thrombocytopenia.罗米司亭在儿童免疫性血小板减少症患者中的作用。
Ther Adv Hematol. 2020 Apr 28;11:2040620720912992. doi: 10.1177/2040620720912992. eCollection 2020.
8
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.更新的原发性免疫性血小板减少症的调查和管理国际共识报告。
Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
9
Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.阿伐曲泊帕用于治疗免疫性血小板减少症和慢性肝病所致血小板减少症。
J Blood Med. 2019 Sep 5;10:313-321. doi: 10.2147/JBM.S191790. eCollection 2019.
10
New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.新型血小板减少症小分子药物：化学、药理学和治疗用途的考虑因素。
Int J Mol Sci. 2019 Jun 20;20(12):3013. doi: 10.3390/ijms20123013.